Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily licensed for the management of type 2 diabetes mellitus and, more recently, obesity
In its discovery-to-proof-of-concept work, it activated both receptors in vitro , improved glucose-dependent insulin secretion and glucose tolerance in animals, and in early human studies lowered fasting glucose and body weight
Without this level of analytical precision, pooled effect estimates will continue to obscure clinically actionable information
Its a higher dose of the same active ingredient
Green tea adds catechins, which have a similar effect
These tools can help address barriers posed by in-person visits, enhance patient engagement, and promote adherence to nutritional and lifestyle recommendations